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Purpose: To determine the relationship between vitamin D status and upper respiratory tract 13 
infection (URTI) of physically active men and women across seasons (study 1). Then, to 14 
investigate the effects on URTI and mucosal immunity of achieving vitamin D sufficiency 15 
(25(OH)D ≥50 nmol·L-1) by a unique comparison of safe, simulated-sunlight or oral D3 16 
supplementation in winter (study 2). Methods: In study 1, 1,644 military recruits were 17 
observed across basic military training. In study 2, a randomized controlled trial, 250 men 18 
undertaking military training received either placebo, simulated-sunlight (1.3x standard 19 
erythemal dose, three-times-per-week for 4-weeks and then once-per-week for 8-weeks) or 20 
oral vitamin D3 (1,000 IU·day
-1 for 4-weeks and then 400 IU·day-1 for 8-weeks). URTI was 21 
diagnosed by physician (study 1) and Jackson common cold questionnaire (study 2). Serum 22 
25(OH)D, salivary secretory immunoglobulin A (SIgA) and cathelicidin were assessed by 23 
LC-MS/MS and ELISA. Results: In study 1, only 21% of recruits were vitamin D sufficient 24 
during winter. Vitamin D sufficient recruits were 40% less likely to suffer URTI than recruits 25 
with 25(OH)D <50 nmol·L-1 (OR (95% CI) = 0.6 (0.4–0.9)); an association that remained 26 
after accounting for sex and smoking. Each URTI caused on average 3 missed training days. 27 
In study 2, vitamin D supplementation strategies were similarly effective to achieve vitamin 28 
D sufficiency in almost all (≥95%). Compared to placebo, vitamin D supplementation 29 
reduced the severity of peak URTI symptoms by 15% and days with URTI by 36% (P < 30 
0.05). These reductions were similar with both vitamin D strategies (P > 0.05). 31 
Supplementation did not affect salivary SIgA or cathelicidin. Conclusion: Vitamin D 32 
sufficiency reduced the URTI burden during military training. 33 
Keywords: cholecalciferol, 25-hydroxyvitamin D, exercise, UVB, immunity, virus.  34 
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Athletes and military personnel experience arduous training and nutritional 36 
inadequacy that may compromise host defense and increase their susceptibility to respiratory 37 
illness such as the common cold, particularly during the autumn-winter (1, 2). The 38 
immunomodulatory effects of vitamin D are considered to play a role in the seasonal stimulus 39 
for upper respiratory tract infection (URTI) (3, 4). This has fuelled considerable interest in 40 
potential prophylactic benefits of vitamin D supplementation on URTI. Vitamin D can be 41 
obtained from diet but is primarily synthesized by skin exposure to sunlight ultraviolet B 42 
(UVB) radiation. As dietary vitamin D intakes in the US and Europe (112–330 IU·day-1, (5-43 
7)) are typically less than recommended (600 IU·day-1, (7, 8)) people who live at latitudes 44 
>35° or live indoors for the majority of sunlight hours and cover-up from the sun are at 45 
higher risk of vitamin D insufficiency. Indeed, epidemiological studies report vitamin D 46 
sufficiency (serum 25-hydroxyvitamin D (25(OH)D) ≥50 nmol·L-1) in only 40–65% of 47 
athletes and military personnel during the winter, when skin exposure to UVB radiation is 48 
negligible (9-11).  49 
Vitamin D is widely accepted to influence both innate and adaptive immunity with 50 
implications for host defense (12, 13). 25(OH)D is converted in the kidney to the biologically 51 
active form 1,25-dihydroxyvitamin D (1,25(OH)2D), which enhances the innate immune 52 
response by the induction of antimicrobial proteins like cathelicidin (13). Antimicrobial 53 
proteins help to prevent URTI as part of the first line of defense. The actions of vitamin D on 54 
adaptive immunity may also be anti-inflammatory or ‘tolerogenic’ (3). Immune tolerance has 55 
been described as the ability to dampen defense yet control infection at a non-damaging level 56 
(14); prompting the search for tolerogenic nutritional supplements to reduce URTI burden 57 
(3). URTI burden can be assessed by URTI prevalence, or the duration or severity of URTI. 58 
As such, maintaining or achieving vitamin D sufficiency may reduce URTI burden by 59 
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preventing URTI symptoms but also by reducing the duration and/or severity of URTI (3, 9, 60 
11)).  61 
Large cross-sectional and randomized, placebo-controlled supplementation studies in 62 
the general population highlight that vitamin D reduces the burden of URTI (4, 15, 16). 63 
However, cross-sectional studies in young healthy and athletic populations present 64 
conflicting findings (17-19), which might be explained by small samples with few URTI, a 65 
limited range of vitamin D concentrations due to single-season data collections, and a lack of 66 
control for factors known to independently influence URTI (e.g. sex and smoking). 67 
Randomized, controlled trials investigating the effect of vitamin D supplementation on URTI 68 
and immunity in military recruits and athletes are extremely limited and present a mixed 69 
picture (20-23). These studies show reduced URTI symptoms (22), improved mucosal 70 
immunity (i.e. salivary cathelicidin and immunoglobulin A (IgA)) (21, 23) and fewer missed 71 
training days due to URTI (20), as well as, no effect on URTI symptoms (20) or mucosal 72 
immunity (22, 23). The significant heterogeneity reported in these trials may stem from 73 
variations in participant baseline vitamin D status and dosing regimens; these factors are 74 
considered to modify the effect of vitamin D on immunity to respiratory pathogens (15). The 75 
participants in these studies were vitamin D sufficient at baseline (20, 21), which likely 76 
limited the need and potential benefit of vitamin D supplementation (11). Also participants 77 
were administered higher oral vitamin D doses than recommended by the Institute of 78 
Medicine (IOM) and European Food Safety Authority (EFSA) (21, 22) increasing the risk of 79 
adverse outcomes (tolerable upper intake 4000 IU·day-1) (7, 8). Although vitamin D is 80 
derived from skin exposure to sunlight the effect of safe skin sunlight exposure on URTI 81 
burden and mucosal immunity has yet to be studied. Ultraviolet (UV) radiation has a range of 82 
vitamin D-dependent and -independent effects on immunity (24); however, whether there are 83 
additional benefits of safe sunlight exposure, compared to oral vitamin D supplementation, is 84 
This article was accepted in its current form to on 23rd December 2020. This is a post-peer-review, pre-copyedit 




unknown. Given the negative impact of URTI on training and performance it is important to 85 
determine whether vitamin D supplementation has measurable and meaningful effects on 86 
URTI in physically active populations (2, 9, 11).  87 
First the relationship between vitamin D status and URTI prevalence was determined 88 
in a large, prospective cohort study of young men and women commencing military training 89 
across all seasons (study 1). It was hypothesized that vitamin D sufficient recruits would be 90 
less likely to suffer URTI, compared to those who had serum 25(OH)D <50 nmol·L-1. Then, 91 
in a randomized, placebo-controlled trial (study 2), the effects on overall URTI burden 92 
(prevalence, duration and severity) and mucosal immunity of achieving vitamin D sufficiency 93 
by either simulated sunlight, following recommendations on safe, low-level sunlight exposure 94 
(25), or oral D3 supplementation, in wintertime was investigated. Vitamin D sufficiency was 95 
targeted because maintaining serum 25(OH)D concentration ≥50 nmol·L-1 has been 96 
recommended for health by the IOM and EFSA and is achievable using safe doses of oral 97 
vitamin D3 and simulated sunlight (7, 8). It was hypothesized that achieving vitamin D 98 
sufficiency during winter by vitamin D supplementation would reduce URTI burden, and 99 
improve mucosal immunity, compared to placebo supplementation. 100 
 101 
METHODS 102 
British Army recruits voluntarily participated in study 1 and study 2 after providing fully 103 
informed written consent and passing a clinician-screened medical assessment, which 104 
excludes for a number of medical conditions, including chronic lung diseases, and asthma 105 
symptoms or treatment in the last year. Men (study 1 and study 2) were located at Infantry 106 
Training Centre Catterick, UK (latitude 54°N), and women (study 1) were located at Army 107 
Training Centre Pirbright, UK (latitude 51°N). All volunteers were studied during 12 weeks 108 
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of Basic Military Training that follows a syllabus of basic military skills including physical 109 
training, weapon handling, map reading, and fieldcraft. The progressive, structured, physical 110 
training program included: endurance training, circuit training, agility-based gymnasium 111 
work, assault course practice, and marching with a load. The studies received ethical approval 112 
from the UK Ministry of Defence Research Ethics Committee and were conducted in 113 
accordance with the Declaration of Helsinki (2013) (study registration references at 114 
www.clinicaltrials.org [NCT02416895, NCT03132103]). 115 
Study one 116 
Participants and study design. 1,644 men and women (n = 1,220 men: 95% white ethnicity, 117 
age 21 ± 3 years; body mass 75.3 ± 9.9 kg, height 1.77 ± 0.06 m, body mass index (BMI) 118 
24.0 ± 2.7 kg·m-2, 38% smokers; n = 424 women: 95% white ethnicity, age 22 ± 3 years, 119 
body mass 64.8 ± 8.2 kg, height 1.65 ± 0.06 m, BMI 23.7 ± 2.4 kg·m-2, 24% smokers) 120 
participated in this prospective cohort study between January 2014 and September 2015. 121 
Participants were included if they gave baseline blood samples and URTI data was available 122 
during the entire 12 weeks of military training.  123 
Experimental procedures. Baseline measures were collected from each participant during 124 
the initial medical assessment; including a venous blood sample for determination of serum 125 
25(OH)D; height and body mass; ethnicity and smoking history by self-reported 126 
questionnaire (Figure 1). Medical records were accessed to obtain physician-diagnosed URTI 127 
and lost training days due to URTI. The URTI were diagnosed by a single general practice-128 
trained physician. A lost training day was recorded when a recruit was unavailable for normal 129 
military training.  130 
Study two 131 
This article was accepted in its current form to on 23rd December 2020. This is a post-peer-review, pre-copyedit 




Participants and study design. 250 men (age 22 ± 7 years, body mass 76.3 ± 10.8 kg, height 132 
1.77 ± 0.06 m, BMI 24.2 ± 3.0 kg·m-2) participated in this double-blind, randomized, 133 
placebo-controlled trial (Figure 1). Participants were recruited at the start of 12 weeks of 134 
Basic Military Training during January and February of 2016 and 2017; when ambient UVB 135 
is negligible at UK latitudes (50–60°N), and serum 25(OH)D is at its annual nadir. 136 
Participants were eligible to participate if they had sun-reactive skin type of I to IV on the 137 
Fitzpatrick Skin Type Scale (26), were not consuming supplements containing vitamin D, and 138 
had not used a sunbed or traveled to a sunny climate in the 3 months before the study.  139 
Experimental procedures. Participants were randomized within their platoons to one of four 140 
intervention groups: 1) oral vitamin D3 supplementation (ORAL); 2) oral placebo 141 
supplementation (ORAL-P); 3) solar simulated radiation (SSR); or, 4) solar simulated 142 
radiation placebo (SSR-P). Block randomization was used (www.randomiser.org) to achieve 143 
an equal distribution of intervention groups within each platoon so any differences in training 144 
conditions between platoons did not influence the outcomes of the study. The intervention 145 
strategy for the SSR and ORAL groups was to restore and then maintain IOM and EFSA 146 
recommended vitamin D sufficiency (serum 25(OH)D ≥50 nmol·L-1). Participants completed 147 
a 4-week restoration phase, necessary because serum 25(OH)D was at its annual wintertime 148 
nadir, followed by an 8-week maintenance phase.  149 
At baseline, during the routine initial medical assessment, height and body mass were 150 
measured, a venous blood sample was collected for the determination of serum 25(OH)D, 151 
and a lifestyle questionnaire was completed to determine smoking and alcohol use. 152 
Additional blood samples were obtained at week 5, and week 12. At baseline, week 5, and 153 
week 12 saliva samples were collected in the evening, between 18:00 and 21:30 h, at least 15 154 
minutes postprandial. Participants were excluded from analysis if they did not achieve ≥80% 155 
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compliance with the intervention. Compliance with the interventions was calculated from 156 
researcher weekly counts of oral capsules remaining in recruit pill boxes and SSR cabinet 157 
visit records. Vitamin D from the diet was estimated in week 12 using a food frequency 158 
questionnaire, and solar UVR exposure was measured in weeks 4 and 11 using polysulphone 159 
badges, worn on the upper chest/anterior shoulder region on the outer clothes, as described 160 
(10, 27). The change in absorbance of the badges due to exposure was measured using a 161 
spectrophotometer and related to the erythemal effective UVR (sunburning) through a 162 
standard polynomial relationship; data are expressed as standard erythemal dose per day (27). 163 
Participant dietary vitamin D intake was calculated excluding the oral D3 supplement 164 
participants received in the ORAL group. On completion of the study, to confirm participant 165 
blinding, participants were asked to guess the intervention they had received. 166 
Simulated sunlight intervention. Simulated sunlight was provided following guidelines on 167 
safe, low-level sunlight exposure for vitamin D synthesis (6); described previously to achieve 168 
serum 25(OH)D ≥50 nmol·L-1 in the majority of individuals with sun-reactive skin type of I 169 
to IV (28). Those assigned to the SSR intervention were exposed three-times-a-week during 170 
the restoration phase and once-per week during the maintenance phase to an experimenter-171 
controlled constant UVR dose using a whole body irradiation cabinet (Hapro Jade, Kapelle, 172 
The Netherlands) fitted with Arimed B fluorescent tubes (Cosmedico, Stuttgart, Germany). 173 
The fluorescent tubes emitted a UVR spectrum similar to sunlight (λ: 290–400 nm; 95% 174 
UVA: 320–400 nm, 5% UVB: 290–320 nm) that was characterized by a spectroradiometer 175 
(USB2000+, Ocean Optics BV, Duiven, The Netherlands) radiometrically calibrated with 176 
traceability to UK national standards.  177 
During each exposure, participants received a 1.3x standard erythemal dose (SED) 178 
whilst wearing shorts and a T-shirt to expose ~40% skin surface area. This dose is equivalent 179 
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to ~15 minutes, midday summer sun exposure six-times-per-week for a casually dressed 180 
individual in northern England (latitude 53.5°N) (28). A constant SSR dose was maintained 181 
during the study by monitoring irradiance using a spectroradiometer (USB2000+, Ocean 182 
Optics BV) and adjusting for any decrease in measured irradiance emitted by increasing 183 
exposure time, as described (28) (mean duration of SSR exposures was 222 ± 23 s). The 184 
exposure time was controlled by using an electronic timer on the irradiation cabinet. For the 185 
SSR-P participants, the number and duration of intervention exposures were the same as 186 
SSR, except the irradiation cabinet fluorescent tubes were covered with transparent UVR 187 
blocking film (DermaGard UV film, SunGard, Woburn, Massachusetts, USA). A 188 
spectroradiometer confirmed the UVR blocking film was effective at preventing transmission 189 
of 99.9% of UVR. 190 
Oral vitamin D3. Participants receiving the ORAL intervention consumed a vitamin D3 191 
capsule daily, containing 1,000 IU and 400 IU during the restoration and maintenance phases, 192 
respectively (Pure Encapsulations, Sudbury, Massachusetts, USA). The restoration dose was 193 
based on previous predictive modeling to achieve serum 25(OH)D ≥50 nmol·L-1 (29), and 194 
pilot investigations that showed it achieved similar serum 25(OH)D concentrations to SSR; 195 
and was less than the tolerable upper intake recommended by the IOM and EFSA (7, 8). The 196 
ORAL maintenance dose was shown in a pilot investigation to maintain serum 25(OH)D ≥50 197 
nmol·L-1 and when accounting for typical habitual dietary intake (5-7) was similar to IOM 198 
and EFSA recommended dietary allowances (7, 8). For 12 weeks, ORAL-P participants 199 
consumed an identical-looking cellulose placebo capsule daily (Almac Group, County 200 
Armagh, UK). Independent analysis found the vitamin D3 content of the 1,000 and 400 IU 201 
capsules to be 1,090 and 460 IU, respectively, and confirmed the placebo did not contain 202 
vitamin D (NSF International Laboratories, Ann Arbor, Michigan, USA). 203 
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URTI diagnosis (study 2). As in study 1, medical records were accessed to obtain data on 204 
physician-diagnosed URTI and lost training days due to URTI. However, URTI was 205 
principally monitored by self-reported daily symptoms recorded using the Jackson common 206 
cold questionnaire (30). A strength of the Jackson common cold questionnaire compared to 207 
physician-diagnosed URTI is that URTI duration and severity, as well as prevalence, can be 208 
assessed. Participants were asked to rate eight symptoms (sneezing, headache, feeling 209 
generally unwell, runny nose, blocked nose, sore throat, cough, chilliness) on a 4-point Likert 210 
scale (not at all = 0, mild = 1, moderate = 2, severe = 3). Data were included when 211 
participants completed ≥80% of their daily Jackson questionnaires. A URTI was defined by a 212 
daily total symptom score of ≥6 for two or more consecutive days (31). Further, average 213 
URTI duration (average duration of all URTI episodes), the peak URTI symptom severity 214 
(maximum URTI severity score on a single day of any URTI episode; maximum possible 215 
peak severity is 24 arbitrary units (AU)), and the total number of days with a URTI during 216 
basic military training for each participant (total days with URTI; military training is 84 days 217 
in total) were also determined. Self-reported URTI data was not reported back to the military 218 
and therefore did not influence physician diagnosis of URTI or lost training days due to 219 
URTI.  220 
Blood analysis (study 1 and 2). Whole blood samples were collected by venipuncture from 221 
an antecubital vein into plain vacutainer tubes (Becton Dickinson, Oxford, UK), and left to 222 
clot for 1 hour. Subsequently, samples were centrifuged at 1500 g for 10 minutes at 4°C and 223 
the serum was aliquoted into universal tubes before being immediately frozen at -80°C for 224 
later analysis. Total serum 25(OH)D was measured with high-pressure liquid 225 
chromatography-tandem mass spectrometry. Analyses were performed in a Vitamin D 226 
External Quality Assurance Scheme certified laboratory (Bioanalytical Facility, University of 227 
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East Anglia, Norwich, UK). The mean intra-assay coefficient of variation (CV) for 25(OH)D3 228 
and 25(OH)D2 were <10% and the lower limit of quantification was 0.1 nmol·L
-1 (32). 229 
Saliva collection and analysis (study 2). Saliva was collected for 5 min in a pre-weighed 30 230 
mL tube using the passive dribble method (33). Samples were weighed immediately after 231 
collection, centrifuged at 1500 g and 4°C for 10 minutes, aliquoted, and then stored at -80°C. 232 
Samples were analyzed in duplicate by enzyme-linked immunosorbent assay for secretory 233 
IgA (SIgA) and cathelicidin concentration (Salimetrics, Pennsylvania, USA, and Hycult 234 
Biotech, Pennsylvania, USA). The mean intra-assay CV was 2.3% for saliva SIgA 235 
concentrations ranging from 0.02 to 0.51 mg·mL-1 and 10.2% for saliva cathelicidin 236 
concentrations ranging from 0.30 to 65.90 µg·L-1. Assuming the density to be 1.00 g·mL-1 for 237 
saliva, the secretion rate was calculated by multiplying the saliva flow rate by concentration 238 
(33). 239 
Statistical analysis. Statistical analyses were performed using SPSS Version 25 (IBM Corp, 240 
NY, US). Data points that were more than three times the interquartile range were deemed as 241 
outliers and removed. Where data were not normally distributed they were transformed using 242 
square-root calculation. Significance was set at P < 0.05. For study 1, an estimated minimum 243 
required sample size of 1,286 was calculated, using a type 1 error (one-tailed) of 5%, a power 244 
of 80%, and an anticipated odds ratio of 1.5 (equivalent to a small effect size), and including 245 
a binomial variable at 20%. This was based on previous literature describing the difference in 246 
URTI prevalence between individuals with low and high vitamin D status whereby, 20% of 247 
individuals with high vitamin D status reported a URTI (4), whilst also anticipating that 20% 248 
of individuals would have low vitamin D status across the whole year (34). Logistic 249 
regression were used to compare vitamin D status (25(OH)D ≥50 vs <50 nmol·L-1 and ≥75 vs 250 
<30, ≥50–<75 and <75 nmol·L-1) with URTI prevalence during twelve-weeks military 251 
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training, and the first three weeks of military training; circulating 25(OH)D has an estimated 252 
three-week half-life (35, 36). Sex and smoking were included as covariates as they have 253 
previously been shown to influence URTI susceptibility (37, 38). Chi-square tests were used 254 
to compare URTI prevalence between vitamin D sufficient participants and those with serum 255 
25(OH)D <50 nmol·L-1, and the proportion of vitamin D sufficient participants between 256 
seasons. We used one-way ANOVA to compare 25(OH)D between seasons. For study 2, an 257 
estimated minimum required sample size of 74 (37 in each comparison group) was 258 
calculated, using the anticipated odds ratio of 0.3 for URTI prevalence between vitamin D 259 
and placebo supplemented individuals with low vitamin D status (15), and that 60% would 260 
self-report URTI during basic military training (18, 31, 39), with a type 1 error (one-tailed) of 261 
5%, and a power of 80%. URTI prevalence between vitamin D (SSR and ORAL) and placebo 262 
(SSR-P and ORAL-P) supplementation groups was compared by logistic regression. 263 
Independent samples t-tests (2 groups (SSR and ORAL combined, SSR-P and ORAL-P 264 
combined)) were used to compare vitamin D and placebo supplementation effects on average 265 
URTI duration, total days with URTI, peak URTI severity, saliva flow rate, SIgA, and 266 
cathelicidin. Serum 25(OH)D, total days with URTI, URTI duration, URTI severity, saliva 267 
flow rate, SIgA, and cathelicidin, were compared between vitamin D strategies, and placebo 268 
groups, by mixed-model ANOVA ((4 groups (SSR, ORAL, SSR-P, and ORAL-P) × 3-time 269 
points (baseline, week 5 and 12)). Sunlight exposure and dietary vitamin D intake between 270 
SSR, ORAL, SSR-P, and ORAL-P groups were compared by one-way ANOVA. Cohen’s d 271 
effect sizes (d) are presented to indicate the meaningfulness of group differences for total 272 
days with URTI, URTI duration, and URTI severity; whereby, values greater than 0.2, 0.5, 273 
and 0.8 represent small, medium and large effects, respectively (40).  274 
 275 
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Study one 277 
Low proportion of wintertime vitamin D sufficiency in healthy young men and women 278 
Baseline serum 25(OH)D concentration was lower in winter than all other seasons (P < 0.01, 279 
Figure 2A); when only 21% of participants were vitamin D sufficient (baseline serum 280 
25(OH)D ≥50 nmol·L-1; Figure 2B).  281 
Vitamin D sufficiency associated with reduced URTI prevalence 282 
A total of 110 URTI episodes were recorded with 7% of participants having at least one 283 
physician-diagnosed URTI. On average, each URTI resulted in 3.4 ± 3.3 lost training days 284 
(4% of total training days). Vitamin D sufficient participants at baseline were 40% less likely 285 
to have a physician-diagnosed URTI, during 12 weeks of training, than participants with 286 
baseline serum 25(OH)D <50 nmol·L-1 (6% vs 9%, respectively, OR (95% CI) = 0.6 (0.4–287 
0.9), P < 0.05, Figure 2C). Vitamin D sufficient participants at baseline were half as likely to 288 
have a URTI within the first three weeks of training than participants with a baseline serum 289 
25(OH)D <50 nmol·L-1 (2% vs 5%, OR (95% CI) = 0.5 (0.3–0.8), P < 0.05); approximately 290 
half of all URTI episodes occurred during this period of training (47%, 52 URTI episodes). 291 
The association between vitamin D status and URTI prevalence remained when controlling 292 
for sex and smoking (P < 0.05). URTI prevalence was not different between participants with 293 
a baseline serum 25(OH)D ≥75 nmol·L-1 and baseline serum 25(OH)D of <30, ≥50–<75, or 294 
<75 nmol·L-1 (P > 0.05).  295 
 296 
Study two  297 
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A flow diagram detailing the number of participants assessed, recruited, and excluded from 298 
the analysis is provided in Figure 3. There were no differences between treatment or control 299 
groups in demographics, anthropometrics, or serum total 25(OH)D at baseline (Table 1 and 300 
Figure 4). During the 12-week intervention, daily sunlight exposure (0.35 ± 0.56 SED·d-1) 301 
and dietary vitamin D were not different between groups (153 ± 136 IU·day-1, P > 0.05). 302 
Participants were sufficiently blinded to the intervention since only 38.4% correctly guessed 303 
their allocated group, 27.3% were incorrect, and 34.3% said they did not know whether they 304 
had received an active or placebo intervention.  305 
Winter simulated sunlight and oral vitamin D3 increased vitamin D sufficiency  306 
At baseline, before wintertime vitamin D supplementation began, only one-quarter (27%) of 307 
participants were vitamin D sufficient. Both SSR and ORAL supplementation strategies were 308 
successful in achieving vitamin D sufficiency in almost all by week 5 (≥95%). Week 5 and 309 
12 serum 25(OH)D concentrations in the SSR and ORAL groups were higher than in the 310 
respective placebo groups (P < 0.001, Figure 4).  311 
Winter vitamin D supplementation reduced URTI burden 312 
A total of 93 Jackson-defined URTI episodes were recorded with 69% of participants having 313 
at least one self-reported URTI. The URTI prevalence was similar in vitamin D and placebo 314 
supplementation groups for the restoration (weeks 1–4), maintenance (weeks 5–12), and 315 
entire 12 week period of training (ORAL and SSR vs ORAL-P and SSR-P 57% vs 63%, 29% 316 
vs 32%, and 71% vs 68%, respectively, P > 0.05). The URTI average duration were also 317 
similar in vitamin D and placebo supplementation groups (Figure 5A, P > 0.05). Winter 318 
vitamin D supplementation reduced URTI burden compared to placebo; whereby, 319 
participants had 15% lower peak URTI severity (P < 0.05; Figure 5B), and 36% fewer total 320 
days with a URTI (P < 0.05; Figure 5C). Participants beginning vitamin D supplementation 321 
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with serum 25(OH)D <50 nmol·L-1 had 33% shorter average URTI duration (P = 0.05; Figure 322 
5D), 21% lower peak URTI severity (P < 0.05; Figure 5E) and 43% fewer total days with 323 
URTI (P < 0.05; Figure 5F), when receiving vitamin D rather than placebo supplementation. 324 
There was no difference in URTI prevalence, duration, severity or total days with URTI 325 
between vitamin D supplementation strategies, or between the different placebo groups (P > 326 
0.05). Specifically, the ORAL and SSR vitamin D supplementation strategies effect on URTI 327 
burden was similar (ORAL vs SSR, URTI prevalence 70% vs 72%, total days with URTI 9.2 328 
± 8.4 vs 8.4 ± 6.7 days, URTI average duration 6.9 ± 5.0 vs 6.5 ± 5.7 days, peak URTI 329 
severity 10.8 ± 3.0 vs 12.3 ± 3.8 AU, all P > 0.05). A physician-diagnosed URTI was 330 
recorded for 8% of recruits, which was comparable to 8% prevalence in the same seasonal 331 
period in study 1, and resulted in 3.3 ± 1.3 training days lost. 332 
Vitamin D supplementation and mucosal immunity  333 
Vitamin D supplementation and placebo groups did not differ at baseline, and weeks 5 and 334 
12, for saliva flow rate, SIgA concentration, SIgA secretion rate, cathelicidin concentration, 335 
and cathelicidin secretion rate (P > 0.05; Table 2).  336 
 337 
DISCUSSION 338 
The primary finding of these two studies was that vitamin D sufficiency reduced the 339 
burden of URTI in healthy young adults completing arduous military training. In study 1, 340 
vitamin D sufficient men and women were 40% less likely to suffer a physician-diagnosed 341 
URTI during training than those with serum 25(OH)D <50 nmol·L-1 (Figure 2). Given this 342 
finding, and that only 21% of participants were vitamin D sufficient during winter, study 2 343 
examined the effect of winter vitamin D supplementation on URTI. Compared to placebo, 344 
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vitamin D supplementation reduced the severity of peak URTI symptoms by 15% and days 345 
with URTI by 36% (Figure 5). Study 2 is the first to demonstrate the benefits of vitamin D 346 
supplementation, in line with IOM and EFSA guidelines, on URTI in an active population. 347 
These findings are timely as the nutrition and athletic performance position stands from the 348 
International Olympic Committee and American College of Sports Medicine highlight that 349 
vitamin D insufficiency is widespread in athletes (9, 41). 350 
In study 1, vitamin D sufficient men and women were less likely to suffer a physician-351 
diagnosed URTI during training than those with serum 25(OH)D of <50 nmol·L-1 (Figure 2). 352 
This finding can be considered robust as it was observed after accounting for sex and 353 
smoking, which is a strength of this study when compared to previous research that has not 354 
controlled for factors known to independently influence URTI (17-19). In study 1, the 355 
association between baseline vitamin D status and URTI was stronger during the first three 356 
weeks of the twelve-week training program, which might be expected given the high 357 
incidence of URTI at this time and that 25(OH)D has approximately a three-week half-life 358 
(35, 36). Study 1 extends our understanding of the relationship between vitamin D and URTI 359 
in active populations as data was collected in a large sample, across all seasons, and with a 360 
large range of serum 25(OH)D concentrations. The burden of URTI was evident as each 361 
URTI resulted in an average of 3 days missed training.  362 
In study 2 vitamin D supplementation by simulated-sunlight and oral vitamin D3 was 363 
similarly effective to achieve IOM and EFSA recommended vitamin D sufficiency in the 364 
majority of individuals (≥95%, Figure 4). Vitamin D supplementation did not reduce self-365 
reported URTI prevalence or benefit mucosal immunity compared to placebo (Table 2). 366 
However, vitamin D supplementation reduced URTI burden compared to placebo: 367 
participants receiving vitamin D reported 15% lower peak URTI severity and 36% fewer 368 
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days with URTI compared to placebo (Figure 5). The magnitude of the reduction in URTI 369 
burden in study 2 can be considered meaningful as effect sizes were medium to large. These 370 
findings also broadly agree with the previous research in this area (20, 22), i.e., vitamin D 371 
supplementation reduced URTI symptoms (22) and absence from duty due to respiratory 372 
infection (20).  373 
The different methods used to assess URTI in the studies may explain the difference 374 
between study 1 and 2 prevalence findings. The lower URTI prevalence in study 1 than study 375 
2 (7% vs 69%) indicates that physician diagnosis of URTI compared to daily self-report 376 
likely missed more minor illnesses that did not warrant a medical visit. Further, study 2 377 
physician-diagnosed URTI prevalence was 8%, which was the same as study 1, when 378 
controlling for season. Self-reported URTI data was not reported back to the military and 379 
therefore did not influence physician diagnosis of URTI or lost training days due to URTI. 380 
When considered carefully in the context of these different methods, the findings of studies 1 381 
and 2 are complementary. In study 2, lower peak URTI severity and fewer days with URTI 382 
with vitamin D supplementation, compared to placebo, would be expected to translate to 383 
vitamin D sufficient individuals reporting less to medical services, and consequently having 384 
fewer physician-diagnosed URTI than those individuals with 25(OH)D <50 nmol·L-1. This is 385 
entirely consistent with the main finding of study 1: URTI prevalence was lower in vitamin D 386 
sufficient individuals than those with 25(OH)D <50 nmol·L-1 (Figure 2).  387 
Study 2 findings are notable as they highlight that vitamin D supplementation may 388 
reduce URTI burden, rather than prevent URTI. Vitamin D supplementation did not influence 389 
the innate mucosal antimicrobial proteins SIgA and cathelicidin that form an important part 390 
of the first line of defense against URTI. Based on these findings it is speculated that the 391 
tolerogenic effects of vitamin D may reduce URTI burden by limiting inflammation in 392 
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response to an infection (i.e., controlling infection at a non-damaging level) (3, 14, 42), which 393 
subsequently leads to a reduction in self-reported URTI severity and duration (14). Future 394 
research is warranted to investigate the effect of vitamin D supplementation on URTI and 395 
circulating anti-inflammatory cytokines (3). To better understand the influence of vitamin D 396 
supplementation on the immune pathway these studies should examine serum 1,25(OH)2D, 397 
the biologically active form, as well as 25(OH)D. It is also worth noting that women were not 398 
included in study 2, and therefore future work should determine the influence of vitamin D 399 
supplementation on URTI burden in women.  400 
The pathological determination of URTI using nasopharyngeal throat swabs would 401 
have provided assurance that URTIs reported in study 1 and 2 were infection by origin, rather 402 
than due to some other cause e.g., allergy. Nonetheless, previous research has shown that 403 
infectious pathogens of URTI identified by self-reported questionnaire methods were 404 
confirmed in 82% of recreationally active men and women (31), and in 75% of Winter 405 
Olympic Games athletes (43). Furthermore, study 2 was completed during winter when 406 
common cold and flu are prevalent, and symptoms caused by summer allergies are rare. 407 
Rejecting self-reported URTI for pathogen recognition is not advocated, rather future 408 
research is advised to use a blended approach incorporating the infectious etiology with real-409 
world URTI symptomology. Study 2 findings highlight the importance of the daily 410 
assessment of URTI symptoms to monitor URTI duration and severity as well as prevalence, 411 
regardless of whether pathogen recognition is available. The assessment of URTI duration 412 
and severity will be important in future studies wishing to further examine potential 413 
tolerogenic effects of vitamin D on immune health. Future research should also adopt the 414 
blended approach to more fully understand the effectiveness of other potential treatments for 415 
URTI. 416 
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Currently, there is no consensus for the optimal vitamin D threshold or dose for 417 
immune health (13). Participants beginning supplementation with serum 25(OH)D <50 418 
nmol·L-1 reported shorter URTI duration when receiving vitamin D compared to placebo 419 
supplementation. Further evidence that participants with serum 25(OH)D <50 nmol·L-1 420 
benefitted more from vitamin D supplementation than the entire sample is clear when 421 
examining the effect sizes between vitamin D and placebo for URTI outcomes; small-422 
medium effect sizes for the entire sample, compared to medium and large effect sizes for 423 
participants with serum 25(OH)D <50 nmol·L-1 (Figure 5). Compared to IOM and EFSA 424 
recommended vitamin D sufficiency, no additional protection from URTI of higher vitamin 425 
D status, including a previously proposed optimal threshold (serum 25(OH)D >75 nmol·L-1) 426 
(44) was revealed. These findings alongside, other findings from this research program that 427 
show benefits of vitamin D sufficiency on in vivo immunity (45), support 25(OH)D ≥50 428 
nmol·L-1 for immune health. Further, the current studies highlight that exercise performance 429 
may indirectly benefit from maintaining vitamin D sufficiency by reducing lost training days 430 
to URTI.  431 
No additional benefit of SSR compared to oral vitamin D3 supplementation was 432 
shown on URTI, immune function (this study and (45)), or exercise performance (10). 433 
Consequently, active people are advised to take the 400 IU·day-1 oral vitamin D3 dose, from 434 
the maintenance phase of study 2, to maintain vitamin D sufficiency when exposure to 435 
ambient UVB is inadequate: between early autumn and late winter, and for those that live 436 
and/or exercise indoors for the majority of sunlight hours or cover-up from the sun. When 437 
accounting for typical dietary vitamin D intake, this oral vitamin D3 supplementation 438 
approach corresponds with current IOM and EFSA recommendations (600 IU·day-1) for bone 439 
and general health and, unlike simulated sunlight, there is no time burden for an individual; 440 
no requirement for bulky irradiation cabinets; and oral vitamin D3 supplementation is 441 
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effective regardless of sun-reactive skin type. Nevertheless, low-level sunlight may provide 442 
benefits to human health, additional to vitamin D synthesis, and this remains an area of active 443 
research (24). 444 
CONCLUSIONS 445 
Vitamin D sufficiency reduced URTI burden in military recruits during arduous 446 
training. In study 1, vitamin D sufficient recruits were less likely to have a URTI compared to 447 
those with serum 25(OH)D <50 nmol·L-1. In study 2, winter vitamin D supplementation, 448 
which achieved vitamin D sufficiency in almost all (≥95%), reduced peak URTI severity, and 449 
total days with URTI compared to placebo. To reduce the burden of URTI, maintaining 450 
vitamin D sufficiency is recommended for military personnel and other active populations, 451 
such as athletes who participate in arduous training.  452 
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FIGURE 1. A schematic of the prospective cohort study (study 1) that investigated the 581 
association between vitamin D status (serum 25(OH)D), upper respiratory tract infection 582 
(URTI) and days lost from training, and the randomized controlled trial (study 2) that 583 
investigated the effects of vitamin D supplementation by solar simulated radiation (SSR), oral 584 
vitamin D3 (ORAL), or placebo (SSR-P or ORAL-P) on URTI and mucosal immunity. Blood 585 
samples were collected at baseline (study 1 and 2), week 5, and the end of week 12 (study 2). 586 
Saliva samples were collected at baseline, week 5 and the end of week 12 (study 2). The 587 
syringe icon represents the blood sample; the head and tube icon represent the saliva sample.  588 
 589 
  590 
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FIGURE 2. Seasonal variation in serum 25(OH)D (panel A), vitamin D sufficiency 591 
prevalence (serum 25(OH)D ≥50 nmol·L-1; panel B), and the URTI prevalence when serum 592 
25(OH)D ≥50 nmol·L-1 or <50 nmol·L-1 (panel C) in 1,644 men and women during 12-weeks 593 
of military training. a, lower than summer, P < 0.05. b, lower than autumn, P < 0.05. c, lower 594 
than spring, P < 0.05. *, lower than participants with serum 25(OH)D <50 nmol·L-1, P < 595 
0.05. Panel A data are mean ± SD. Panels B and C are percentages represented by vertical 596 
bars. 597 
 598 
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FIGURE 3. Flow diagram of the randomized controlled trial (study 2) investigating the 599 
effects of vitamin D supplementation on upper respiratory tract infection (URTI) and mucosal 600 
immunity. Flow diagram indicates the number of participants assessed, randomized to solar 601 
simulated radiation (SSR) or oral vitamin D3 (ORAL), or a placebo (solar simulated radiation 602 
placebo (SSR-P) or oral placebo (ORAL-P)), and statistically analyzed for URTI, salivary 603 
secretory immunoglobulin A (SIgA), and cathelicidin.  604 
 605 
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FIGURE 4. Serum 25(OH)D in men completing military training whilst receiving 12-weeks 606 
of vitamin D supplementation (solar simulated radiation (SSR) or oral vitamin D3 (ORAL)) 607 
or a placebo (solar simulated radiation placebo (SSR-P) or oral placebo (ORAL-P)). 608 
Combined vitamin D interventions (SSR and ORAL) vs combined placebo (SSR-P and 609 
ORAL-P; panel A), ORAL vs ORAL-P (panel B), and SSR vs SSR-P (panel C). *, greater 610 
than placebo, P < 0.05. †, greater than baseline, P < 0.05. ‡, greater than week 5, P < 0.05. 611 
Data are mean ± SD. 612 
 613 
This article was accepted in its current form to on 23rd December 2020. This is a post-peer-review, pre-copyedit 




FIGURE 5. Upper respiratory tract infection (URTI) average duration (panel A & D), peak 614 
URTI severity (panel B & E), and total days with URTI during military training (panel C & 615 
F), in the vitamin D supplementation (SSR and ORAL) vs placebo supplementation groups 616 
(SSR-P and ORAL-P) in all participants (left-hand column) and participants with a baseline 617 
25(OH)D <50 nmol·L-1 (N = 62; right-hand column). * and #, lower than placebo, P < 0.05 618 
and P = 0.05, respectively. Data are mean ± SD. d = Cohen’s d effect size. a maximum 619 
possible peak severity (24 arbitrary units (AU)), b total number of days for military training 620 
(84 days).  621 
 622 
623 
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TABLE 1. Study 2 baseline participant demographics, anthropometrics, and lifestyle 624 
behaviors in solar simulated radiation (SSR), SSR placebo (SSR-P), oral vitamin D3 (ORAL), 625 
and oral placebo (ORAL-P) supplemented groups. 626 
Data are presented as mean ± SD unless otherwise stated. There were no differences in demographics, 627 
anthropometrics, or lifestyle behaviors between groups (P > 0.05).  628 
  629 
 SSR  
(N = 63) 
SSR-P  
(N = 59) 
ORAL  
(N = 63) 
ORAL-P  
(N = 65) 
Demographics      
Age (years) 21 ± 3 22 ± 3 21 ± 3 23 ± 12 
Ethnicity (White Caucasian) [n (%)] 61 (98) 57 (97) 63 (100) 65 (100) 
Skin type (I, II, III, IV) [n (%)] 4 (7), 16 (26), 
33 (53), 9 (15) 
4 (7), 16 (27), 
28 (48), 11 (19) 
5 (8), 18 (29), 
33 (52), 7 (11) 
3 (5), 19 (29), 
29 (45), 14 (22) 
Anthropometrics      
Height (m) 1.78 ± 0.06 1.78 ± 0.06 1.77 ± 0.07 1.78 ± 0.06 
Body mass (kg) 76 ± 11 77 ± 11 75 ± 11 77 ± 10 
BMI (kg·m-2) 24 ± 3 24 ± 3 24 ± 3 24 ± 3 
Lifestyle behaviors      
Alcohol user [n (%)] 51 (82) 47 (80) 55 (87) 51 (78) 
Smoker [n (%)] 23 (37) 25 (42) 26 (41) 21 (32) 
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TABLE 2. Influence of 12-weeks solar simulated radiation (SSR), placebo solar simulated 630 
radiation (SSR-P), oral vitamin D3 (ORAL), and oral placebo (ORAL-P) on saliva flow rate 631 
(FR), SIgA concentration, SIgA secretion rate (SR), cathelicidin concentration and 632 
cathelicidin SR.  633 
  SSR SSR-P ORAL ORAL-P 
FR (µL·min-1) Baseline 205 ± 128 184 ± 181 260 ± 214 241 ± 173 
ΔBaseline to 
week 5 
+5 ± 124 +26 ± 160 -36 ± 159 -5 ± 208 
ΔBaseline to 
week 12 † ‡ 




Baseline 0.14 ± 0.08 0.12 ± 0.06 0.13 ± 0.06 0.12 ± 0.05 
ΔBaseline to 
week 5 † 
+0.01 ± 0.08 +0.04 ± 0.09 +0.02 ± 0.09 +0.02 ± 0.07 
ΔBaseline to 
week 12 † 
+0.00 ± 0.05 +0.03 ± 0.06 +0.03 ± 0.1 +0.03 ± 0.09 
SIgA SR 
(µg·min-1) 
Baseline 27 ± 17 18 ± 11 26 ± 19 25 ± 17 
ΔBaseline to 
week 5 
-2 ± 22 +12 ± 16 +1 ± 18 +1 ± 20 
ΔBaseline to 
week 12 † ‡ 




Baseline 14 ± 11 14 ± 14 13 ± 13 12 ± 11 
ΔBaseline to 
week 5 
-8 ± 16 +6 ± 18 -2 ± 10 -1 ± 15 
ΔBaseline to 
week 12 
-5 ± 14 +1 ± 19 -4 ± 16 -1 ± 17 
Cathelicidin SR 
(ng·min-1) 
Baseline 3.25 ± 3.04 1.69 ± 1.91 2.42 ± 2.28 3.13 ± 4.79 
ΔBaseline to 
week 5 
-0.82 ± 3.82 +0.96 ± 1.81 -0.54 ± 1.78 -1.35 ± 4.25 
ΔBaseline to 
week 12 
-0.70 ± 4.10 +2.15 ± 3.61 +0.14 ± 2.45 -0.64 ± 5.60 
Main effect of time vs baseline, † P < 0.05. Main effect of time vs week 5, ‡ P < 0.05. Data are mean 634 
± SD. 635 
